Next Generation Risk Markers in Preventive Cardio-oncology

Lamberg, Morgan; Rossman, Andrea; Bennett, Alexandra; Painter, Sabrina; Goodman, Rachel; MacLeod, James; Maddula, Ragasnehith; Rayan, David; Doshi, Krishna; Bick, Alexander; Bailey, S N; Brown, Sherry-Ann

doi:10.1007/s11883-022-01021-x

Cited by 2 publications

(3 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4, 5 ) and treatment-related cardiac dysfunction ( 6, 7 ). Currently, there are no guideline recommendations with respect to CVD screening for patients with cancer, possibly stemming from the lack of CVD-related markers that can better risk-stratify patients with cancer beyond existing cardiovascular risk factors for the general population ( 8 ). The identification and development of biomarkers that can eventually be used towards a risk assessment tool for the purpose of discriminating patients diagnosed with cancer who are at a higher risk of CVD may be useful ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors

Sun

Sandoval

Perreault

et al. 2023

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared to the general population. We sought to evaluate the impact of mosaic chromosomal alterations (mCAs) on death of CVD causes, coronary artery disease (CAD) causes, and of any cause in patients with a cancer diagnosis. Methods: The study was a prospective cohort analysis of 48,919 UK Biobank participants with a cancer diagnosis. mCAs were characterized using DNA genotyping array intensity data and long-range chromosomal phase inference. Multivariable Cox regression models were used to ascertain the associations of mCAs. Exploratory endpoints included various incident cardiovascular phenotypes. Results: Overall, 10,070 individuals (20.6%) carried ≥1 mCA clone. In adjusted analyses, mCA was associated with an increased risk of death of CAD causes (HR: 1.37, 95% CI: 1.09-1.71, P=0.006). In sub-analyses, we found that carriers of mCAs diagnosed with kidney cancer had an increased risk of death of CVD causes (HR: 2.03, 95% CI: 1.11-3.72, P=0.022) and CAD causes (HR: 3.57, 95% CI: 1.44-8.84, P=0.006). Women diagnosed with breast cancer who carried a mCA also had a higher risk of death of CAD causes (HR: 2.46, 95% CI: 1.23-4.92, P=0.011). Conclusions: Among cancer survivors, carriers of any mCA are at an increased risk of CAD death compared to non-carriers. Mechanistic studies should be considered to better ascertain the biological mechanisms underneath the observed associations between mCAs and cardiovascular events for specific cancer types. Impact: There may be clinical relevance in considering mCAs in patients diagnosed with cancer and undergoing treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors

Sun

Sandoval

Perreault

et al. 2023

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Currently, there are no guideline recommendations with respect to CVD screening for patients with cancer, possibly stemming from the lack of CVD-related markers that can better risk-stratify cancer patients beyond existing cardiovascular risk factors for the general population. 8 The identification and development of biomarkers that can eventually be used towards a risk assessment tool for the purpose of discriminating patients diagnosed with cancer who are at a higher risk of CVD may be useful. 8…”

Section: Introductionmentioning

confidence: 99%

“…8 The identification and development of biomarkers that can eventually be used towards a risk assessment tool for the purpose of discriminating patients diagnosed with cancer who are at a higher risk of CVD may be useful. 8…”

Section: Introductionmentioning

confidence: 99%

Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors: an analysis of the UK Biobank

Sun

Sandoval

Lemieux-Perreault

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared to the general population. Here, we evaluated the impact of somatic mosaic chromosomal alterations (mCAs) on death of CVD causes, coronary artery disease (CAD) causes, from cancer, and of any cause in patients with a cancer diagnosis within the UK Biobank (n=48 919). mCAs were derived from DNA genotyping array intensity data and long-range chromosomal phase inference from participants. Overall, 10 070 individuals (20.6%) carried ≥1 mCA clone. In adjusted analyses, mCA was associated with an increased risk of death of CAD causes (hazard ratio [HR]: 1.37, 95% confidence interval [CI]: 1.09-1.71, P=0.006), from cancer (HR: 1.06, 95% CI: 1.00-1.11, P=0.041), and death of any cause (HR: 1.07, 95% CI: 1.02-1.12, P=0.005). Among cancer survivors, carriers of any mCA are at an increased risk of death of CAD causes and of any cause as compared to non-carriers.

show abstract

Next Generation Risk Markers in Preventive Cardio-oncology

Cited by 2 publications

References 78 publications

Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors

Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors

Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors: an analysis of the UK Biobank

Contact Info

Product

Resources

About